Introduction {#Sec1}
============

Within a few months of Rector Wilhelm Conrad Roentgen announcing to the Physico-Medical Society of Würzburg, Germany, on December 28, 1895, that a new type of rays ("x-rays") could penetrate skin and visualize the skeleton, physicians around the world were using this modality to diagnose broken bones and locate bullets within human flesh. Since this enlightened inception, imaging in its many forms has been central to the investigation of bone disease. Particularly during the past three decades, advances in technology have enabled noninvasive bone imaging to evolve dramatically from examination of bone macrostructure and pathology to include the study of bone microstructure, physiology, and pathophysiology \[[@CR1]•\].

The aim of osteoporosis screening and treatment is to prevent bone fracture. A fracture occurs when the external force to a bone exceeds its strength. The ability of any bone to resist fracture depends on the amount and distribution of bone as well as its intrinsic properties \[[@CR2]\]. The ultimate aims of bone imaging in osteoporosis are to minimize fracture occurrence by identifying the osteoporotic process at an early stage, before significant bone loss occurs; differentiate distinctive patterns of bone loss; accurately predict individual fracture risk; and precisely monitor treatment response. This review introduces some of the new imaging modalities and analytical techniques for bone that have emerged, been enhanced, or been adapted to a new clinical application during the past 3 to 4 years. To put these new advances in perspective, we first briefly discuss the background to each imaging modality and the existing clinical application.

Bone Mineral Density Measurement {#Sec2}
================================

Dual X-ray Absorptiometry {#Sec3}
-------------------------

Bone mineral density (BMD) measurement by dual x-ray absorptiometry (DXA) has been available for clinical use since 1987 and is currently the most readily available surrogate marker of bone strength and fracture risk, with fracture risk increasing approximately 1.6-fold for every SD decrement in BMD measurement irrespective of gender \[[@CR3]--[@CR5]\]. DXA is limited in that it assesses only areal BMD (BMDa, in g/cm^2^) such that, for example, in the spine, vertebral depth is not taken into account. DXA is also limited in that it is a composite measure of both cortical and trabecular bone and prone to overestimation of BMD from degenerative-type hyperostosis.

Recommendations from the International Society for Clinical Densitometry regarding DXA examination for all ages and both genders have been updated \[[@CR6]\]. Although DXA is predictive of fracture risk in cohort studies, such epidemiologic evidence cannot be readily applied on an individual patient basis in clinical practice. To address this limitation, individual fracture risk has been standardized using the World Health Organization Fracture Risk Assessment tool (FRAX), which was released in 2009 \[[@CR7], [@CR8]\]. FRAX combines BMD from DXA with other risk factors (eg, age, sex, height, previous fracture) to provide a 10-year risk of hip and other major insufficiency fractures \[[@CR7], [@CR8]\]. FRAX is mainly applicable to osteopenic (low bone mass) patients, as the results do not influence the clinical management of patients with normal BMD or osteoporosis \[[@CR8]\]. Although it is not an ideal system, FRAX represents an important initiative in allowing clinicians to individualize fracture risk based on DXA examination and other factors \[[@CR8]\].

As well as assessing bone density, improvements in fan beam DXA technology have enabled DXA systems to acquire moderately high-resolution images of the thoracic and lumbar spine \[[@CR9]\]. These lateral vertebral DXA images are useful for detecting moderate or severe vertebral fractures (\>90% sensitivity and specificity) but limited in the assessment of mild vertebral fractures \[[@CR8]\]. This vertebral fracture assessment provides clear added benefit to the overall assessment by DXA and is recommended in settings in which the result will alter clinical management \[[@CR6]\]. In a study of more than 5,000 unselected community-based women 75 years of age or older, lateral vertebral DXA images were sufficient to gauge fracture status in 92% of vertebrae from T8 to L3, and of these women, nearly 15% had a vertebral fracture. Over a median follow-up period of 4 years, those with prevalent vertebral fracture had a 2.01 relative risk compared with those without vertebral fracture of developing any further osteoporotic fracture, and a 2.29 relative risk for hip fracture. These risks were even greater in patients with more than two prevalent vertebral fractures, increasing to 2.54 and 3.94, respectively \[[@CR10]\].

Quantitative CT {#Sec4}
---------------

The value of quantitative CT (QCT) in allowing volumetric densitometry (measured in mg/cm^3^) of the trabecular and cortical bony components was recognized in the late-1970s \[[@CR11]--[@CR13]\]. QCT can specifically detect changes in the more metabolically active trabecular bone, making it a more sensitive discriminator of BMD changes than DXA \[[@CR14]\]. For example, during a 1-year follow-up of postmenopausal women, a twofold to threefold greater increase in trabecular BMD was shown by QCT in response to parathyroid hormone compared with integral BMD by DXA \[[@CR15]\]. The main limitations of QCT regarding BMD measurements are that a clinical CT scanner is required and a larger radiation dose than that with DXA is incurred.

Worldwide, many tens of thousands of thoracic and abdominal CT examinations are performed daily on clinical patients \[[@CR16]\]. Several recent studies have shown how it is possible to obtain meaningful QCT BMD data from patients undergoing thoracoabdominal CT examinations for other clinical reasons without the use of a calibration phantom. Such "phantom-less" BMD data have a high correlation (*R*^*2*^ = 0.95) with BMD data obtained from QCT over a wide range of densities \[[@CR17]•\]. An internal reference such as subcutaneous fat or paravertebral lean muscle \[[@CR17]•\], or a correction factor \[[@CR18]\] is used to counteract the lack of an external reference phantom. Phantom-less CT has been studied in patients undergoing noncontrasted CT studies for coronary artery calcium scoring \[[@CR18]\], CT colonoscopy, or standard QCT \[[@CR17]•\]. Even for contrasted CT examinations, a correction factor adjusting for contrast enhancement can be applied \[[@CR19]\]. Phantom-less CT can be applied reasonably to cross-sectional clinical studies, though it should not be used in longitudinal studies, as the precision for phantom-less CT is less than that on standard QCT \[[@CR17]•\], especially if contrast has been administered.

These studies demonstrate that it is technically feasible to obtain reasonably accurate QCT BMD spine data in patients undergoing thoracic or abdominal CT examinations for other reasons. Although it may seem appropriate to provide such (unrequested) data as a routine addendum to clinical CT reports, several important practical and clinical questions should be addressed before proceeding down this path \[[@CR20]\]. For example, would such additional BMD information, which is time consuming and costly to acquire, be of long-term clinical benefit? Would this BMD information be properly managed by the referring clinician (or patient), or would it merely encourage the additional inappropriate use of substantial health resources in terms of clinical management, treatment, and follow-up \[[@CR20]\]?

Bone Quality Assessment {#Sec5}
=======================

As BMD accounts for only part of the variation seen in bone strength and only some of the observed reduction in fracture risk that occurs with treatment, recent developments have focused more on measuring bone structure and quality of both trabecular and cortical bone rather than bone mass alone. This is done with the knowledge that a measure encompassing bone quality and structure along with bone mass will provide a better prediction of fracture risk than bone mass alone.

Radiography {#Sec6}
-----------

Radiography is a low-cost, readily available technique with high spatial resolution capable of providing fine bone detail, especially of distal appendicular skeleton such as the distal forearm and phalanges. Although it is ideally suited for use in large population studies, the limitation of radiography is that as a projectional imaging technique, it cannot consistently visualize individual trabeculae and depends heavily on the depth of tissues under investigation. With increasing sophistication of structural analysis techniques and an improving ability to acquire high-resolution radiographic detail, interest remains in developing radiography to more precisely evaluate trabecular bone detail \[[@CR21]\]. A new radiographic device capable of delivering digitized high-resolution radiographs de novo is an advance on previous devices, which required digitization of high-resolution radiographs prior to structural analysis. The number of steps in data analysis is thus reduced, with less potential for introducing error. A new bone texture analysis method known as *Laws' masks* was applied to these high-resolution digitized radiographs to study trabecular bone architecture in the calcaneus in more than 300 postmenopausal women and was able to distinguish those with fracture from those without fracture independent of BMD and with reasonable reproducibility \[[@CR21]\].

Multidetector CT and Volumetric Quantitative CT {#Sec7}
-----------------------------------------------

In the 1990s, analytical techniques were applied to high-resolution CT data in a quest to find structural parameters predictive of bone strength. This research gained impetus in the new millennium with the arrival of multidetector CT (MDCT) systems that allowed higher spatial resolution, improved delineation of bone architecture, and faster acquisition of volumetric QCT (vQCT) datasets. Since its inception, the number of detector rows on clinical CT units has increased from 4 to the current clinical standard of 64 rows, although 320-row MDCT systems are also commercially available. Comparing 64-row (in-plane pixel size, 234 μm; slice increment, 300 μm) and 320-row MDCT (in-plane pixel size, 234 μm; slice increment, 250 μm) in assessing distal radial trabecular pattern, 320-row MDCT conferred little practical advantage over 64-row MDCT. Both systems yielded different absolute measures, although they still correlated highly (*r* = 0.92--0.96; *P* \< 0.0001) with a reference standard for bone volume fraction and trabecular spacing. However, as expected, they fared less well with trabecular thickness and number because the spatial resolution of all MDCT systems (250--300 μm) remains larger than the trabecular thickness of 50 to 200 μm \[[@CR22]\]. Nevertheless, structural parameters by MDCT provide a better discriminator of change than DXA. For example, in 65 postmenopausal women, teriparatide increased apparent bone volume fraction by 30.6% ± 4.4% (mean±SE), and apparent trabecular number by 19.0% ± 3.2%, compared with a 6.4% ± 0.7% increase in DXA-derived BMDa \[[@CR23]\].

Medical Image Analysis Framework {#Sec8}
--------------------------------

High-precision software known as *medical image analysis framework* (MIAF) has been developed to facilitate analysis of vQCT datasets \[[@CR24], [@CR25]\]. MIAF enables the automatic determination of anatomic coordinates to yield predetermined volume of interests for analysis (Fig. [1](#Fig1){ref-type="fig"}). This automated anatomic coordinate system facilitates longitudinal study as well as study of the relative contributions of density, geometry, and trabecular and cortical bone to mechanical failure. Using this advanced image analysis system to study proximal femoral failure load, cortical variables were found to predict as much (59%) failure load as trabecular variables (52%), which was in agreement with previous studies showing that trabecular bone contributes more to subcapital bone strength, while cortical bone contributes more to intertrochanteric bone strength \[[@CR26]\]. MIAF can also enable recognition of bone areas most influenced by treatment. For example, ibandronate treatment for 1 year increased volumetric density in the subcortical and extended trabecular areas of the proximal femur, as well as in the extended cortical and superior/inferior trabecular regions of the vertebral body, all of which are mechanically significant areas \[[@CR27]••\]. Fig. 1Volumetric quantitative CT of the lumbar spine with automated anatomic coordinates outlining the periosteal, endosteal, and juxta-endosteal ("peeled") contours of the vertebral body. Several different volume of interests (VOIs) can be evaluated, such as the total, trabecular, peeled, elliptical, and Pacman VOIs in the axial plane, as well as the superior, mid-vertebral, and inferior VOIs in the sagittal plane. (*Image courtesy of* Klaus Engelke)

Finite Element Analysis Modeling {#Sec9}
--------------------------------

Finite element analysis (FEA) modeling is being increasingly incorporated into noninvasive bone imaging and can be used to improve QCT estimation of bone strength and stiffness in vivo. High-resolution CT (or MRI) imaging data are converted into "voxel" finite element models following segmentation of cortical and trabecular bone to yield measures of bone strength (Fig. [2](#Fig2){ref-type="fig"}). High correlation is present between predicted strength and actual strength for the vertebral body, proximal femur, or distal radius \[[@CR28]--[@CR30]\]. FEA improves insight into the pathophysiology and treatment of vertebral fractures. For example, FEA analysis of vQCT vertebral body data in young and older men and women revealed, as expected, that vertebral body strength decreased with age twice as much in women as in men \[[@CR31]••\]. This difference was primarily due to a greater reduction in cortical bone strength in women, with trabecular compartment strength declining to a comparable degree in both sexes \[[@CR31]••\]. In other words, differential vertebral body cortical bone loss between men and women probably accounts in part for the higher vertebral fracture rate seen in women \[[@CR31]••\]. Vertebral volumetric BMD, vertebral apparent cortical thickness, overall vertebral compressive strength by FEA, and load-to-strength ratio were found to be less in females with mild vertebral fractures than in nonfractured controls and least in women with moderate to severe vertebral fractures, emphasizing how fracture severity and the presence of a fracture are indicators of relative vertebral strength \[[@CR32]•\]. Fig. 2Volumetric quantitative CT provides a basis for finite element analysis of the proximal femur. Note how stress distribution as related to color code is highest along the inferomedial aspect of the femoral neck and proximal shaft. (*Image courtesy of* Klaus Engelke)

Regarding treatment, FEA analysis of vQCT datasets from female rheumatoid arthritis patients showed that alendronate prevented the median 10% loss in vertebral strength observed in nontreated controls and that this alendronate effect was primarily due to a positive effect on cortical rather than trabecular bone \[[@CR33]\]. In comparing the antiresorptive agent (alendronate) with a bone-forming agent (teriparatide) over an 18-month period, both treatments improved vertebral body strength, but the effect was more pronounced with teriparatide, which preferentially improved volumetric density and strength of the trabecular component \[[@CR34]\]. This enhanced effect of teriparatide was evident only on finite element modeling and not on DXA or QCT total integral density data \[[@CR34]\]. Finite element modeling revealed how treatment with teriparatide over 2 years improved vertebral body strength by as much as 30% during simulated compression and bending \[[@CR35]•\]. This was a much better improvement in bone strength than predicted by density change alone \[[@CR35]•\].

Similarly, for the proximal femur, FEA analysis of vQCT data can be used clinically to study longitudinal changes in bone strength and relate these to concurrent structural changes. Comparing aged-related changes in femoral strength with femoral neck BMDa, decreases in femoral strength with aging (55% decrease in women, 39% decrease in men) were greater than for femoral neck BMDa (26% decrease in women, 21% decrease in men). Femoral strength declined notably for women during their mid-40s and for men during their mid-50s \[[@CR36]••\]. Also, the prevalence of "low femoral strength" (\<3,000 N) was much higher than that of BMD-based "osteoporosis" \[[@CR36]••\]. This is notable because femoral strength assessment by FEA has been shown to be more predictive of proximal femoral fracture than BMDa \[[@CR37]••\]. FEA also has been applied to assess treatment effects in the proximal femur. Treatment of severely osteoporotic postmenopausal women with teriparatide for 24 months resulted in a significantly improved femoral buckling ratio, not at 12 months, but at 24 months, while bending strength parameters (ie, section modulus) also improved compared with baseline \[[@CR38]•\]. These bone strength indices were associated with an increase (4.3%) in proximal femoral cortical cross-sectional area due to endosteal rather than periosteal bone apposition \[[@CR38]•\]. Future studies will help confirm whether this improved treatment evaluation afforded by FEA also translates into improved fracture prediction.

Peripheral Quantitative CT {#Sec10}
--------------------------

Dedicated peripheral QCT (pQCT) systems with a resolution comparable to that of MDCT (500 μm) have been available---though not widely used---since 1990 to examine the peripheral skeleton. These systems confer a smaller effective radiation dose and are particularly useful for studying cortical bone changes in metabolic bone disorders because the distal radius contains more cortical bone than the vertebral body. A pQCT study has shown how cortical bone loss begins during middle age for women, though much later in men (after age\~75 years), whereas trabecular bone loss begins in early adulthood for both sexes \[[@CR39]\]. By age 50 years, approximately 40% of total lifetime trabecular loss has occurred, although only 15% of cortical bone loss has occurred by that point \[[@CR39]\]. As pQCT units use low-power x-ray tubes, these examinations are slow, with a tendency toward motion artefact. With this limitation in mind, the feasibility of using clinical CT scanners with a dedicated forearm phantom as an alternative to pQCT has been investigated \[[@CR40]•\]. BMD data (from both cortical and trabecular bone) as well as geometric data (cortical thickness, cortical BMD, and density-weighted polar moment of inertia \[a measure of bone strength\]) are obtainable from the diaphysis to ultradistal radius with good accuracy and very good precision in less than 30 s, compared with about 4 min for dedicated pQCT systems \[[@CR40]•\]. Applying a clinical CT scanner to study the effect of denosumab, a human monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor-κB ligand), on the distal radius of osteopenic postmenopausal women revealed a positive effect on both the cortical and trabecular bone compartments, as well as bone strength---estimated by density-weighted polar moment of inertia---compared with placebo \[[@CR41]\]. This indicates how a clinical CT system can be used as a good alternative to pQCT systems to assess the distal forearm. This also applies to the experimental study of small animals \[[@CR42]•\].

High-Resolution Peripheral Quantitative CT {#Sec11}
------------------------------------------

Bridging the clinical need for an imaging modality with lower radiation dose, yet with better spatial resolution is the high-resolution pQCT scanner (HR-pQCT) (XtremeCT, Scanco Medical, Brüttisellen, Switzerland). This can evaluate bone architecture in the distal radius and tibia with an isotropic voxel of 82 μm^3^ (spatial resolution\~120 μm), though with an effective radiation dose about 0.1 of that for MDCT of the more central skeleton. Even at this much improved resolution, individual trabeculae (50--150 μm thick) still fill only one to two voxels, leading to considerable partial volume averaging. The result is that trabecular spacing (400--800 μm wide) can be accurately assessed, but modest limitations still exist in measuring trabecular number and thickness (50--150 μm), although these difficulties are considerably less than with MDCT. In 2005, the first published clinical study assessing HR-pQCT found that postmenopausal women had lower BMD, trabecular number, and cortical thickness compared with premenopausal women at the distal radius and tibia, although spine and hip BMDa were similar \[[@CR43]\]. Compared with healthy controls, HR-pQCT revealed increased cortical porosity in postmenopausal osteopenic/osteoporotic women \[[@CR44]\] and also in diabetics, especially those with osteoporotic fracture \[[@CR45]\]. Comparing systemic lupus erythematosus patients on steroids with and without vertebral fracture, no BMDa differences were apparent on spine DXA examination, although several key cortical and trabecular structural parameter differences were apparent on HR-pQCT examination of the distal radius (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR46]•\]. HR-pQCT is clearly a useful modality for assessing changes in cortical and trabecular bone structural parameters, with a precision of about 2% to 5% \[[@CR43]\]. The main limitations of HR-pQCT are that it requires a dedicated scanner, is confined to examination of the distal forearm and leg, has some difficultly with registration in the Z plane (longitudinal plane), and should take into consideration the expected difference among individuals of short or long radial or tibial bone length. Fig. 3High-resolution peripheral quantitative CT (XtremeCT; Scanco Medical, Brüttisellen, Switzerland) of the distal radius. **a**, Systemic lupus erythematosus (SLE) patient on steroids without vertebral fracture. **b**, SLE patient on steroids with vertebral fracture. Note the relative deterioration in trabecular architecture and thinning with increased porosity of cortex in the patient with vertebral fracture compared with the patient without vertebral fracture. (*Image courtesy of* Edmund Li)

MRI {#Sec12}
---

Although the spatial resolution of MRI is less than that of other techniques, such as MDCT, it does possess several other advantages that will ensure its increasing deployment to bone research for the foreseeable future. In addition to not using ionizing radiation, it can directly acquire images in any plane de novo and has the potential to derive functional information from bone and bone marrow not readily available with other imaging techniques. Since its first clinical bone applications in 1977 \[[@CR1]•, [@CR47]\], improvements in coil technology, pulse sequencing, analytical techniques, and gantry hardware have advanced the usefulness of MRI in all aspects of bone imaging, including osteoporosis research (Fig. [4](#Fig4){ref-type="fig"}). For example, medullary canal signal-to-noise ratio is up to 16 times better with 3.0-T magnetic resonance (MR) than with 1.5-T MR \[[@CR48]\], which contributes to in vitro trabecular bone architecture being better delineated at 3.0 T than 1.5 T using micro-CT as a reference standard \[[@CR49]\]. Fig. 4High-resolution in vivo MRI of the distal radius and ulna. The *circle* in the midportion of the distal radius represents an area selected for virtual core biopsy as shown. (*Image courtesy* of Felix Wehrli)

Most MR-based analyses of bone architecture have been performed on the distal radius, the distal tibia, and the calcaneus because these sites contain more trabecular bone and are more easily evaluated with MR surface coils. As the in vivo, in-plane resolution achievable with MRI is 200 to 300 μm, it is not possible to delineate individual trabeculae. Nevertheless, apparent trabecular structural parameters derived from MRI correlate quite favorably with those derived from higher-resolution techniques such as histology or micro-CT \[[@CR50], [@CR51]\]. However, absolute structural parameters from HR-pQCT and high-resolution MRI were not found to be comparable (*P*\<0.0001), with trabecular bone fraction and trabecular thickness being three to four times larger with MRI than with HR-pQCT \[[@CR52]\].

MRI has the potential to examine physiologic parameters within bone and bone marrow beyond the mineralized component \[[@CR1]•\]. Applying sequences with ultra-short echo times allows detection of molecules with ultra-short T2 relaxation times, such as water, within highly ordered tissues such as cortical bone or tendon. Quantification of the emitted signal provides an index of cortical bone water content as a potential parameter of bone strength. Using a technique validated in sheep and human tibial specimens, water content of the tibial diaphysis was higher in postmenopausal women than premenopausal women and much higher in women with chronic renal failure on hemodialysis, even though no difference in tibial volumetric BMD was found among the three groups \[[@CR53]\].

At the moment, there is no noninvasive imaging modality capable of imaging bone matrix (ie, the collagenous lattice onto which the mineralized component \[mainly calcium phosphate\] of bone is deposited). This collagen component and the degree of collagen cross-linking are important for bone strength. Using a specifically designed reference phantom (simulating bone matrix composition of collagen) and a specifically designed MR pulse sequence known as WASPI (water- and fat-suppressed proton projection MRI), porcine cortical and trabecular bone samples were evaluated \[[@CR54]\]. A very high correlation (*r*^*2*^ = 0.98 and 0.95) between WASPI intensity values and gravimetric and amino acid analyses, respectively, was observed, indicating that WASPI sequences appear capable of measuring the bone matrix mass density in g/cm^3^ \[[@CR54]\].

By quantifying the phosphorus component of bone mineral, phosphorus spectroscopy (^31^PMRS) can be used to measure BMD. The ratio of BMD/bone matrix density therefore provides a measure of the degree of "bone matrix mineralization" \[[@CR54]\]. Applying these techniques, clear differences in the bone matrix density and degree of bone matrix mineralization were found comparing ovarectomized rats, partially nephrectomized rats, and control rats \[[@CR55]••\]. For the bone cortex, no significant differences were observed between controls and ovarectomized rats. However, for nephrectomized rats, MR study revealed a clear reduction in cortical BMD (decreased by 22%), bone matrix density (decreased by 10%), and extent of bone matrix mineralization (decreased by 12%). For trabecular bone, BMD was seen to be reduced in ovarectomized rats (decreased by 40%) and nephrectomized rats (decreased by 27%), although only the ovarectomized rats showed a reduction in bone matrix density (decreased by 38%), while instead the nephrectomized rats showed a reduction in extent of bone matrix mineralization (decreased by 26%) compared with controls \[[@CR55]••\]. It is also technically feasible to undertake WASPI imaging in humans, offering exciting prospects for clinical research \[[@CR56]\].

Vertebral Fracture Recognition {#Sec13}
------------------------------

The quest for ever-finer determination of bone structure and quality should not override the day-to-day recognition of another much more tangible and immediately clinically relevant parameter of bone quality. The presence of an insufficiency fracture, of which vertebral fracture is by far the most frequent, provides indisputable evidence of reduced bone strength irrespective of BMD or other measurement. However, in clinical practice, vertebral and other insufficiency fractures frequently go unnoticed or unreported \[[@CR57], [@CR58]\]. The incentive of the "vertebral fracture initiative" is to promote recognition among clinical radiologists and clinicians of the importance of vertebral fracture and to ensure that such fractures, whether they be on chest radiography, abdominal radiography, or thoracoabdominal CT studies, are reported in a standardized, unambiguous fashion \[[@CR59]--[@CR61]\].

Conclusions {#Sec14}
===========

The past 3 to 4 years have seen the exponential growth of bone imaging across several complementary modalities continue from its infancy more than 30 years ago. These recent advances in bone imaging---both experimental and practical---have provided significant inroads into the understanding of the prevalence, disease progression, and pathophysiology of metabolic bone disease, particularly osteoporosis. This newfound knowledge has already begun to translate into everyday clinical practice. This trend will continue such that in the not-too-distant future, modifications of new imaging modalities will become more widely available and thus will allow for greatly improved recognition, treatment, and monitoring of the osteoporotic process.
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